Page 5 - Expanded Access Program News Today

Pharming Group reports second quarter and first half 2023 financial results RUCONEST® business performed strongly in 2Q 2023;...

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

NEW YORK, Sept. 1, 2023 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it...

Looking to buy CBD oil in Idaho, but not sure what is legal and what isn’t? We look at how is CBD legal in Idaho and how to buy it.

A significant turnaround materialized for Blue Apron (NYSE: APRN), sparking unseen investor support: a brief overview on developments.

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Earnings Call Transcript August 15, 2023 TFF Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.14 EPS, expectations were $0.2. Operator: Good morning, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Second Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being […]

RHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment; The...

Delcath Systems, Inc. announced that the US Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable... -Yesterday at 09:10 pm- MarketScreener

A deconstructed view on Delcath Systems' (NASDAQ: DCTH) latest FDA approval and key points that are important for investors to understand.

Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.